Sanofi

Por favor elegí tu país para conocer sobre los productos disponibles

Mucosolvan® 24 horas

Mucosolvan® 24 horas contiene micro perlas de ingrediente activo que es liberado en el cuerpo para brindarte un alivio efectivo de la tos durante el día y la noche; brindando 24 horas de tratamiento efectivo para la tos con flema en una sola cápsula diaria.2

Descripción

Mucosolvan® 24 horas tiene triple acción5,6,7

Mucosolvan® tres vías de acción5,6,7
  1. Disuelve la flema
  2. Libera las vías
  3. Protege tus pulmones

Por un máximo de 24 horas, día y noche2

Dosificación

Adultos
1 cápsula cada 24 horas

Ingredientes

Ambroxol 75 mg
Blister por 10 unidades

Prospecto interno

Como los productos y sus regulaciones difieren levemente de un país a otro, por favor consultá el prospecto adjunto

Download

Mucosolvan® 24 horas Cápsulas para la tos

"1. Grassi C, Luisetti M, Rose V de, Fietta A, Sacchi F, Genghini M, et alBiomedical and functional changes in bronchoalveolar parameters induced by ambroxol treatment of chronic bronchitis.International Symposium Surfactant System of the Lung, Rome, 1983 March 2-4 In: Cosmi EV, Scarpelli EM, editors. Pulmonary Surfactant System. Amsterdam: Elsevier, 361 - 370 (1983)"
2. Prevention of Chronic Bronchitis Exacerbations with Ambroxol (Mucosolvan Retard) An Open, Long-Term, Multicenter Study in 5,635 Patients' Respiration 1989;55(suppl l):84-96
"3. Schulz M, Haemmerlein A, Hinkel U, Weis G, Gillissen ASafety and usage pattern of an over-the-counter ambroxol cough syrup: a community pharmacy-based cohort study.Int J Clin Pharmacol Ther 44 (9), 409 - 421 (2006)"
Claim 12 horas:
4 Tai-jun Hang, Meng Zhang, Min Song, Jian-ping Shen, Yin-di Zhang. Simultaneous determination and pharmacokinetic study of roxithromycin and ambroxol hydrochloryde in human plasma by LC-MS/MS (2007). P07-07778
Claim triple mecanismo de acción:
5 Grassi C, Luisetti M, Rose V de, Fietta A, Sacchi F, Genghini M, et al. Biomedical and functional changes in bronchoalveolar parameters induced by ambroxol treatment of chronic bronchitis.International Symposium Surfactant System of the Lung, Rome, 1983 March 2-4 In: Cosmi EV, Scarpelli EM, editors. Pulmonary Surfactant System. Amsterdam: Elsevier , 361-370 (1983) P83-94424
6 Chianese R, Maiorano V, Bisceglie A, Carnimeo N. Controlled clinical trial of a new preparation for the treatment of hypersecretive bronchial pneumopathies.
Arch Med Interna 35 (2) , 139-154 (1983). P85-1211
7 Bonzi G, Reguzzoni G, Geromino A, Negri L. Clinical evaluation of ambroxol in the treatment of acute and chronic broncopneumopathy.
Minerva Pneumol 23 (1) , 61-65 (1984) P85-1431

Disclaimer

Using this link will let you leave a website of Sanofi or to a different domain under the control of Sanofi. In the event that the linked site is not under the control of Sanofi but under the control of a third party or an affiliate in the Sanofi group of companies, Sanofi shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by Sanofi of the site.